Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL news (Ticker: AVR), a resource for investors and traders seeking the latest updates and insights on ANTERIS TECHNOLOGIES GLOBAL stock.
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) generates news primarily around its structural heart programs, clinical data and capital markets activities. As a company focused on medical instruments and supplies for structural heart disease, its announcements center on the development of the DurAVR Transcatheter Heart Valve (THV) System and related regulatory and trial milestones.
Investors following AVR news will see regular updates on clinical outcomes for DurAVR THV in patients with severe aortic stenosis, including small aortic annulus cohorts. Recent releases have detailed 30‑day and one‑year results from pooled analyses of patients treated in the EMBARK Study and early feasibility studies in the United States and Europe, highlighting hemodynamic performance, effective orifice areas, paravalvular leak rates, valve‑related mortality and prosthesis‑patient mismatch metrics.
News coverage also tracks the progress of the PARADIGM Trial, Anteris’ global prospective randomized controlled trial comparing DurAVR THV with commercially available TAVR devices. Key items include first European regulatory clearance from the Danish Medicines Agency, first patients enrolled and treated in Denmark, and U.S. FDA approval of the Investigational Device Exemption to initiate the trial, with recruitment in the United States subject to Institutional Review Board approval.
Beyond clinical data, Anteris issues updates on quarterly financial results, cash flows and operating expenditure linked to regulatory work, trial preparation and manufacturing scale‑up for DurAVR THV. Additional news items cover capital raising transactions involving common stock, CHESS Depositary Interests and warrants, as well as corporate governance events such as special meetings and the annual meeting of stockholders.
For readers tracking AVR, this news stream offers insight into the pace of clinical development, regulatory interactions, trial execution and financing activities that shape the company’s structural heart strategy.
Anteris (NASDAQ: AVR) reported 2025 results and a corporate update, highlighting initiation of the global pivotal PARADIGM Trial, FDA IDE approval in Q4 2025, favorable 30‑day (100 patients) and 1‑year (65 patients) DurAVR clinical outcomes, ISO 13485 progress, and board additions.
Net operating cash outflows were $77.8M; R&D was $69.1M; SG&A was $26.1M. The company completed aggregate capital raises of $320M in early 2026, including a strategic investment from Medtronic.
Anteris (NASDAQ: AVR) announced that CEO Wayne Paterson will present at two investor conferences in March 2026: TD Cowen on March 2, 2026 and Barclays on March 10, 2026. Both appearances include fireside chats and 1x1 meetings with webcasts available.
Webcast links and replays (archived for up to 90 days) are available via the company investor presentations page.
Anteris Technologies (NASDAQ: AVR) announced completion of a $90 million strategic investment from Medtronic, closing immediately after an underwritten common stock offering for a combined $320 million in gross proceeds on Jan 22, 2026. The capital is intended to fund the global pivotal PARADIGM trial and advance commercialization of the DurAVR® Transcatheter Heart Valve (THV). Wells Fargo Securities served as sole placement agent for the Medtronic investment. Management described the funding as validation of the program and said the investment could expand into additional strategic collaboration areas.
Anteris Technologies Global Corp (NASDAQ: AVR) announced the closing of a public offering of 40,000,000 common shares and a private placement of 15,652,173 shares to Medtronic, each at $5.75 per share. Gross proceeds from both transactions were approximately $320 million before fees and expenses. Underwriters included Barclays, Wells Fargo Securities and Cantor; Wells Fargo acted as placement agent for the Medtronic sale. The company said net proceeds will fund the global pivotal PARADIGM Trial for the DurAVR THV, expand manufacturing, support R&D for v2vmedtech, and for working capital and general corporate purposes.
Anteris Technologies Global Corp (NASDAQ: AVR) priced a public offering of 34,782,609 shares at $5.75 per share, generating approximately $200.0 million in gross proceeds, with expected closing on January 22, 2026.
The company granted underwriters a 30-day option to buy an additional 5,217,391 shares. Separately, Anteris agreed to a private placement to Medtronic of up to $90.0 million of shares at the same price, subject to a minimum purchase equal to 16.0% and a maximum of 19.99% of post-offering outstanding shares; the private placement is contingent on the Offering.
Net proceeds are intended to fund the global pivotal PARADIGM Trial for the DurAVR THV, expand manufacturing, support R&D at v2vmedtech, and for working capital.
Anteris Technologies Global Corp (NASDAQ: AVR) announced a proposed public offering of $200.0 million of common stock with a 30-day underwriter option for an additional $30.0 million. Concurrently, Anteris agreed to a private placement with Medtronic for up to $90.0 million of shares at the public offering price, subject to a minimum purchase equal to 16.0% and a maximum of 19.99% of outstanding shares after the Offering. Completion of Medtronic's Private Placement is contingent on completion of the Offering; the Offering is not contingent on the Private Placement.
Proceeds, together with existing cash, are intended to fund the PARADIGM pivotal trial for the DurAVR THV, manufacturing expansion, R&D for v2vmedtech, working capital, and general corporate purposes. Barclays, Wells Fargo Securities and Cantor are joint book-runners; Wells Fargo is placement agent for the private placement.
Anteris Technologies (NASDAQ: AVR) presented 30-day pooled outcomes for 100 small‑annulus severe aortic stenosis patients treated with the DurAVR® THV at PCR London Valves (Nov 17, 2025).
Key results: mean pressure gradient 8.2 ± 3.1 mmHg, effective orifice area 2.2 ± 0.3 cm2, 0 valve‑related deaths, 0 moderate/severe paravalvular leak, and 97% freedom from moderate/severe prosthesis‑patient mismatch; technical success was 100% in the last 50 consecutive implants. The analysis pools EMBARK and early feasibility studies and represents ~20% of planned PARADIGM randomized cohort enrollment.
Anteris (NASDAQ: AVR) reported Q3 2025 results and a corporate update focused on advancing the PARADIGM pivotal trial and scaling manufacturing. Key regulatory milestones included FDA approval to commence U.S. recruitment announced in November 2025 and Danish Medicines Agency approval with the first PARADIGM patients treated in Denmark in October 2025. The company progressed site readiness across the U.S., Europe and Canada, advanced QMS and ISO 13485 preparation, and continued manufacturing scale-up for DurAVR THV production.
Financial highlights: net operating cash outflows $59.3M for the nine months ended Sept 30, 2025; R&D $16.8M and SG&A $5.8M for Q3; cash and cash equivalents of $9.1M at Sept 30, 2025.
Anteris (NASDAQ:AVR) announced that the U.S. Food and Drug Administration granted approval to initiate the PARADIGM global Investigational Device Exemption (IDE) clinical trial for the DurAVR® Transcatheter Heart Valve (THV) on November 3, 2025. The randomized pivotal trial will compare the DurAVR biomimetic valve to commercial TAVR devices in patients with severe calcific aortic stenosis and is intended to support a future PMA submission.
The company said U.S. patient recruitment can now begin, and noted the trial recently launched with first patients treated in Denmark. The study is co-chaired by Dr. Michael J. Reardon and Professor Stephan Windecker.
Anteris (NASDAQ: AVR) reported one-year pooled outcomes for the DurAVR® Transcatheter Heart Valve (THV) in patients with small aortic annuli (mean annulus area 396 ± 37 mm2).
Key results: EOA 2.1 ± 0.2 cm2, mean pressure gradient 8.6 ± 2.6 mmHg, no valve-related mortality and no moderate or severe paravalvular leak at one year; 30-day prosthesis-patient mismatch was 1.5% versus 11.2%–35.3% for current devices. The pooled cohort included 65 small-annulus patients from EMBARK and a US early feasibility study; >100 patients have been implanted overall. Results will be evaluated further in the randomized PARADIGM pivotal trial (NCT07194265).